Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · IEX Real-Time Price · USD
17.59
-1.04 (-5.58%)
At close: Mar 28, 2024, 4:00 PM
17.10
-0.49 (-2.80%)
After-hours: Mar 28, 2024, 5:25 PM EDT

Enliven Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Selling, General & Admin
18.967.77139.545.112.44
Research & Development
64.5731.0238.4432.1519.018.24
Operating Expenses
83.5338.7951.4441.724.1210.68
Operating Income
-83.53-38.79-51.44-41.7-24.12-10.68
Other Expense / Income
-11.95-1.13-0.06-0.34-0.650.66
Pretax Income
-71.58-37.66-51.38-41.36-23.46-11.34
Net Income
-71.58-37.66-51.38-41.36-23.46-11.34
Preferred Dividends
0007.8600
Net Income Common
-71.58-37.66-51.38-49.22-23.46-11.34
Shares Outstanding (Basic)
3635300
Shares Outstanding (Diluted)
3635300
Shares Change
1037.74%-42.31%55.56%1882.29%--
EPS (Basic)
-2.01-12.05-9.48-14.12-133.60-64.56
EPS (Diluted)
-2.01-12.05-9.48-14.12-133.60-64.56
Free Cash Flow
-61.42-32.69-46.78-37.42-22.02-8.78
Free Cash Flow Per Share
-1.73-10.46-8.64-10.75-125.37-49.98
EBITDA
-70.98-37.45-51.29-41.26-23.43-11.34
Depreciation & Amortization
0.60.220.10.10.030
EBIT
-71.58-37.66-51.38-41.36-23.46-11.34
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).